Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 24, 2007, Pages 7765-7772

  Hanna, Mona M ^a   Eid, Nahed M ^a   George, Riham F ^a   Safwat, Hani M ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

3 Phenyltropines; Antidepressant; Norepinephrine; Serotonin; Tropinone

Indexed keywords

3 (4' BROMOPHENOXY) 8 METHYL 3 PHENYL 8 AZABICYCLO[3.2.1]OCTANE; 3 (4' CHLOROPHENOXY) 8 METHYL 3 PHENYL 8 AZABICYCLO[3.2.1]OCTANE; 3 (4' CYANOPHENOXY) 3 (4'' FLUOROPHENYL) 8 METHYLAZABICYCLO[3.2.1]OCTANE; 3 (4' CYANOPHENOXY) 8 METHYL 3 PHENYL 8 AZABICYCLO[3.2.1]OCTANE; 8 METHYL 3 (3' TRIFLUOROMETHYLPHENOXY) 3 PHENYL 8 AZABICYCLO[3.2.1]OCTANE; 8 METHYL 3 (4' NITROPHENOXY) 3 PHENYL 8 AZABICYCLO[3.2.1]OCTANE; 8 METHYL 3 (4' TRIFLUOROMETHYLPHENOXY) 3 PHENYL 8 AZABICYCLO[3.2.1]OCTANE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; MALE; MOUSE; NEUROTOXICITY; NONHUMAN;

5-HYDROXYTRYPTOPHAN; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CITALOPRAM; CLOMIPRAMINE; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FLUOXETINE; MICE; MOLECULAR STRUCTURE; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TROPANES; YOHIMBINE;

MUS;

EID: 35348833081     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.08.055     Document Type: Article

References (32)

1. In: Murray C.J.L., and Lopez A.D. (Eds). The Global Burder of Disease (1996), Harvard University Press, Cambridge, MA
2. Iversen, L.; Glennon, R. A. In Burger's Medicinal Chemistry and Drug discovery; 6th ed.; Antidepressants; Abraham, D. J., Ed.; John Wiley and Sons, Inc.: Canada, 2003; Vol. 6.
3. Stahl S.M. J. Clin. Psychiatry 59 4 (1998) 5
4. Perez V., Puigdemont D., Gilaberte I., Alvarez E., and Artigas F. J. Clin. Psychopharmacol. 21 1 (2001) 36
5. Mongeau R., Blier P., and de Montigny C. Brain Res. Rev. 23 (1997) 145
6. Einarson T.R., Addis A., Mittmann N., and Iskedjian M. Can. J. Clin. Pharmacol. 5 (1998) 205
7. Rickels K. Biol. Psychiatry 1 (1991) 345
8. Hemrick-Luecke S.K., Fuller R.W., and Snoddy H.D. J. Pharmacol. Exp. Ther. 269 (1994) 132
9. Tollefson, G. D.; Thompson, R. G.; Heiligenstein, J. H.; James, S.; Wong, D. T.; Faries, D. L. Am. Coll. Neuropsychopharmacol. 1993.
10. Anttila S., and Leinonen E. Curr. Opin. Investig. Drugs 3 (2002) 1217
11. Shaw A.M., Boules M., Zhang Y., Williams K., Robinson J., Carlier P.R., and Richelson E. Eur. J. Pharmacol. 555 (2007) 30
12. Skolnick P., Popik P., Janowsky A., Beer B., and Lippa A.S. Eur. J. Pharmacol. 461 (2003) 99
13. El Ahmed Y., Maillet P., Laurent E., Talab A., Teste J.F., and Cedat M.J. Eur. J. Med. Chem. 32 (1997) 205
14. Helsley, G. C.; Davis, L.; Olsen; G. E. EP0333026, 1989.
15. Zhao L., Johnson K.M., Zhang M., Flippen-Anderson J., and Kozikowski A.P. J. Med. Chem. 43 (2000) 3283
16. Blough B.E., Keverline K.I., Nie Z., Navarro H., Kuhar M.J., and Carroll F.I. J. Med. Chem. 45 (2002) 4029
17. Hoepping A., Johnson K.M., George C., Flippen-Anderson J., and Kozikowski A.P. J. Med. Chem. 43 10 (2000) 2064
18. Zhang A., Zhou G., Rong S.-B., Johnson K.M., Zhang M., and Kozikowski A.P. Bioorg. Med. Chem. Lett. 12 (2002) 993
19. Zhou J., Kläß T., Zhang A., Johnson K.M., Wang C.Z., Ye Y., and Kozikowski A.P. Bioorg. Med. Chem. Lett. 13 (2003) 3565
20. Zhou J., Kläß T., Johnson K.M., Gliberson K.M., and Kozikowski A.P. Bioorg. Med. Chem. Lett. 15 (2005) 2461
21. Fuller R.W., Wong D.T., and Robertson D.W. Med. Res. Rev. 11 1 (1991) 17
22. Cope A.C., and D'Addieco A.A. J. Am. Chem. Soc. 73 (1951) 3419
23. Perregaard J., Mollzen E.K., Meier E., and Sanchez C. J. Med. Chem. 38 11 (1995) 1998
24. March J. Advanced organic chemistry, Reactions, Mechanisms and Structures. Fourth ed (1992), John Wiley & Sons Inc, New York p.641
25. Spiniello M., and White J.M. Org. Bimol. Chem. 1 (2003) 3094
26. Klaus, E.; Hans-Peter, K.; Heinz-Guenter, M.; Hartmann, S. US4333942, 1982.
27. Jain M.P., Thakur R.S., and Rao P.R. Res. & Ind. 20 (1975) 3
28. Chou T.-S., and Cheng W.-J. Bull. Inst. Chem. Acad. Sin. 29 (1982) 9
29. Altomare A., Cascarano G., Giacovazzo C., Guagliardi A., Burla M.C., Polidori G., and Camalli M. J. Appl. Crystallogr. 27 (1994) 435
30. Mackay, S.; Gilmore, C. J.; Edwards, C.; Stewart, N.; Shankland, K. maXus Computer Program for the Solution and Refinement of Crystal Structures. Bruker Nonius, The Netherlands; MacScience, Japan & The University of Glasgow, 1999.
31. Vogel H.G. Drug discovery and evaluation, pharmacological assays; antidepressant activity. second ed. (2002), Springer-Verlag, Berlin Heidelberg p 570, 571
32. Litchfield J.T., and Wilcoxon F. J. Pharmacol. Exp. Therap. 96 (1949) 99